International Biotech Trust — Results analysis from Kepler Trust Intelligence

IBT outperformed its benchmark with a 64.7% NAV gain and 73.6% share price surge.

What the company is saying

International Biotechnology Trust (LSE:IBT) highlights a 64.7% NAV per share gain for the year ending 31 August 2026, outpacing the Nasdaq Biotechnology Index's 52.3% return. The trust emphasizes its 73.6% share price increase and the acquisition of 13 portfolio companies, which accounted for approximately 27% of NAV, citing Crinetics, Apellis, and Terns as notable contributors. The announcement frames these acquisitions as key drivers of performance and underscores the trust's increased unquoted investment commitment with Schroders Capital, raised from £10m to £25m, with £6.2m invested as of 30 June 2026. Management attributes post-year-end NAV weakness to a sector-wide sell-off linked to US rate hikes, positioning this as an external macroeconomic factor. The trust's managers project continued elevated M&A activity, referencing large-cap pharma's $400bn in revenues at risk by 2033 and recent bid activity, such as a 130% premium for Silence Therapeutics, to support their outlook. The tone is confident, with a focus on both realised outperformance and future sector opportunity.

What the data suggests

The trust delivered a 64.7% NAV per share gain and a 73.6% share price increase for the year to 31 August 2026, both exceeding the Nasdaq Biotechnology Index's 52.3% return. Thirteen portfolio company acquisitions, representing about 27% of NAV, contributed to these results, though the specific impact of each is not quantified. The trust increased its commitment to unquoted investments with Schroders Capital from £10m to £25m, with £6.2m deployed by 30 June 2026, indicating a strategic allocation toward private markets. Recent sector M&A activity included a 130% premium paid for Silence Therapeutics, illustrating robust deal-making. The report notes that post-year-end, NAV has weakened due to a sector sell-off linked to US rate hikes, but does not provide figures for the decline. The data is strong for the reported period, but lacks detail on post-year-end NAV movement and on the realised returns from the increased unquoted allocation.

Analysis

The announcement is anchored by strong, realised performance metrics: a 64.7% NAV per share gain, 73.6% share price increase, and 13 acquisitions representing 27% of NAV, all for the year to 31/08/2026. These are supported by clear numerical disclosures and benchmark comparisons. However, some narrative elements—such as attributing returns to specific acquisitions without quantifying their individual impact, and projecting elevated M&A activity based on large-cap pharma revenue risks—are forward-looking or qualitative and not directly evidenced. The increase in unquoted commitments (from £10m to £25m, with £6.2m invested as of 30/06/2026) signals a substantial capital outlay, but the benefits of this allocation are not yet realised or quantified. The tone is optimistic, and while most claims are factual, the outlook for further M&A and private market opportunities is speculative. The gap between narrative and evidence is moderate, with most hype stemming from forward-looking statements about sector dynamics and future returns rather than exaggeration of current results.

Risk flags

• ●Post-year-end NAV has weakened amid a sector-wide sell-off linked to US rate hikes, introducing immediate downside risk that is not yet quantified in the disclosure. This could erode some of the reported outperformance if the trend continues.
• ●The trust has materially increased its unquoted investment commitment, raising exposure to private markets where liquidity is lower and valuation transparency can be limited. Only £6.2m of the £25m commitment had been invested by 30 June 2026, so the performance of this allocation remains untested.
• ●The narrative attributes strong returns to acquisition activity and sector dynamics, but does not break down the specific contribution of each acquisition or quantify the impact of macroeconomic factors. This lack of attribution detail makes it harder to assess the repeatability of the reported performance.
• ●The expectation of elevated M&A is based on large-cap pharma facing $400bn of revenues at risk by 2033, but this is a sector-wide projection rather than a guarantee of future returns for IBT. If M&A activity slows or valuations compress, future performance could diverge from management's outlook.

Bottom line

IBT delivered a standout year, with a 64.7% NAV gain and a 73.6% share price rise, both well ahead of the sector benchmark. The trust's results were driven by a wave of portfolio company acquisitions, representing 27% of NAV, and an assertive move into unquoted investments, though the latter's returns are not yet visible. Management's bullish outlook for further M&A is grounded in sector fundamentals, notably $400bn in large-cap pharma revenues at risk, but future gains are subject to macroeconomic headwinds, as seen in the post-year-end NAV decline tied to US rate hikes. The lack of detail on post-year-end NAV and on the realised impact of new unquoted investments leaves some open questions. Investors should focus on how the trust navigates current sector volatility and whether its private market bets deliver measurable returns. The most important takeaway is that IBT's active strategy has delivered strong results, but sustaining this outperformance will depend on execution in a more challenging market environment.

Announcement summary

(LSE:IBT) International Biotechnology Trust reported a 64.7% NAV per share gain for the year to 31/08/2026. The Nasdaq Biotechnology Index returned 52.3% over the same period. The share price of International Biotechnology Trust increased by 73.6% during the year. Thirteen portfolio companies were acquired, representing approximately 27% of NAV. Notable acquisitions included Crinetics, Apellis, and Terns, which drove returns for the trust. Following the year-end, the trust's NAV has weakened amid a sector sell-off linked to US rate hikes. The trust increased its unquoted commitment with Schroders Capital from £10m to £25m. As of 30/06/2026, £6.2m had been invested in this unquoted commitment. The managers expect elevated M&A activity as large-cap pharma companies face approximately $400bn of revenues at risk to 2033. Recent bid activity included a 130% premium for Silence Therapeutics. The report attributes the strong performance to the acquisition activity and sector dynamics. The trust's managers believe the current environment is conducive to further M&A. The sector sell-off post-year-end is linked to macroeconomic factors, specifically US rate hikes. The trust's increased commitment to unquoted investments reflects confidence in private market opportunities. The 130% premium for Silence Therapeutics is cited as an example of robust bid activity. The managers' outlook is shaped by the significant revenue at risk for large-cap pharma. The trust's performance exceeded its benchmark index by a notable margin.

Disagree with this article?